Displaying 25 - 36 of 52
Metabolism, Alcohol & Toxicity
8

Sanofi: "Global Liver Health Forum 2023" - EASL Congress 2023

View
General Hepatology
5

Grifols: "The burden of hepatic encephalopathy and albumin as potential approach" - EASL Congress 2023

View
General Hepatology
5

Grifols: "The burden of hepatic encephalopathy and albumin as potential approach" - EASL Congress 2023

View
General Hepatology
5

Grifols: "The burden of hepatic encephalopathy and albumin as potential approach" - EASL Congress 2023

View
Metabolism, Alcohol & Toxicity
6

Takeda: "Alpha-1 antitrypsin deficiency (AATD) - Associated liver disease: More common than you may think" - EASL Congress 2023

View
Metabolism, Alcohol & Toxicity
6

Takeda: "Alpha-1 antitrypsin deficiency (AATD) - Associated liver disease: More common than you may think" - EASL Congress 2023

View
Metabolism, Alcohol & Toxicity
6

Takeda: "Alpha-1 antitrypsin deficiency (AATD) - Associated liver disease: More common than you may think" - EASL Congress 2023

View
Metabolism, Alcohol & Toxicity
6

Takeda: "Alpha-1 antitrypsin deficiency (AATD) - Associated liver disease: More common than you may think" - EASL Congress 2023

View
Metabolism, Alcohol & Toxicity
6

Takeda: "Alpha-1 antitrypsin deficiency (AATD) - Associated liver disease: More common than you may think" - EASL Congress 2023

View
General Hepatology
7

E-Scopics: “Innovations in point-of-care ultrasound for the management of NAFLD-NASH: seeing is believing” - EASL Congress 2023

View
General Hepatology
7

E-Scopics: “Innovations in point-of-care ultrasound for the management of NAFLD-NASH: seeing is believing” - EASL Congress 2023

View
General Hepatology
7

E-Scopics: “Innovations in point-of-care ultrasound for the management of NAFLD-NASH: seeing is believing” - EASL Congress 2023

View
Displaying 25 - 36 of 52